Abstract CT153: Phase I trial of intratumoral administration of autologous <i>CCL21</i> gene-modified dendritic cells in combination with pembrolizumab for advanced NSCLC: Feasibility of repeated IT injectionsBin Liu, Steven M. Dubinett, Camelia Dumitras et al.|Cancer Research|2024Cited by 1